Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

Targeted Genetics acquires Biocontrol

Targeted Genetics Corporation, today announced the completion of the acquisition of Biocontrol Limited.

7 Jan 2011

BG Medicine enters agreement to develop galectin-3 test for Siemens' automated immunoassay platforms

BG Medicine, Inc. announced today that it has entered into an agreement with Siemens Healthcare Diagnostics Inc., a division of Siemens Healthcare, one of the world's largest suppliers of clinical diagnostics to the healthcare industry, for the development and commercialization of a galectin-3 test for Siemens' automated immunoassay platforms for clinical laboratories.

7 Jan 2011

Findings of AM095 in various in vitro, in vivo models of fibrotic disease published in JPET

Amira Pharmaceuticals, Inc. announced today the publication of its findings in the Journal of Pharmacology and Experimental Therapeutics which describes the biologic effects and the characterization of AM095, a lysophosphatidic acid receptor 1 antagonist, in various in vitro and in vivo models of fibrotic disease.

6 Jan 2011

Scientists identify prognostic biomarker to treat patients with HCV

Scientists at Inserm and Institut Pasteur have performed biomarker discovery on patients being treated for chronic hepatitis C infection. Their work, published in The Journal of Clinical Investigation, demonstrates that the plasma levels of the protein IP-10 predict, prior to treatment initiation, the efficacy of treatment with pegylated-interferon and ribavirin.

6 Jan 2011

Bacteria adopt defence strategy to promote antibiotic resistance

Genetic resistance to antibiotics is not the only trick bacteria use to resist eradication- they also have a second defence strategy known as persistence that can kick in.

6 Jan 2011

DARA BioSciences provides additional details of DB959 Phase I study for Type 2 Diabetes

DARA BioSciences, provided additional details from the recently completed Phase I clinical study for DB959, its PPAR delta/gamma agonist, an oral drug in development for the treatment of Type 2 Diabetes.

6 Jan 2011

DARA BioSciences closes registered public offering

On December 28, 2010, DARA BioSciences, Inc. announced that it planned to raise up to $4 million through a registered public offering of units comprised of shares of Series A convertible preferred stock and warrants to purchase shares of common stock. Due to strong demand for the offered securities, the Company increased the size of the offering to up to $4.8 million.

5 Jan 2011

Vitamin D deficiency could be linked to development of certain autoimmune lung diseases

A new study shows that vitamin D deficiency could be linked to the development and severity of certain autoimmune lung diseases.

4 Jan 2011

Peptide in blood and tissue inhibits growth of breast tumors

Researchers at Wake Forest University Baptist Medical Center (WFUBMC) have discovered what may become a new weapon in the fight against breast cancer. For the first time, a peptide found in blood and tissue has been shown to inhibit the growth of human breast tumors in mice, according to a study recently published in the journal Cancer Research.

4 Jan 2011

Lyophilized amniotic membrane in strabismus surgery can cause severe fibrosis

Postoperative adhesions are a major complication in strabismus surgery. Amniotic membrane has been used in the hopes of preventing these adhesions by forming a biological barrier during healing. In an article in the December 2010 issue of the Journal of AAPOS, a team of researchers from Cairo University have discovered that the new approach may also have the opposite effect.

4 Jan 2011

Top-line results of TIGER-2 Phase 3 clinical trial for CF treatment

Inspire Pharmaceuticals, Inc. announced today the top-line results from its second Phase 3 clinical trial, TIGER-2, with denufosol tetrasodium for the treatment of cystic fibrosis.

3 Jan 2011

Children more likely to suffer from appendicitis in areas with few pediatricians

Children who live in areas with fewer pediatricians are more likely to suffer life-threatening ruptures of the appendix than those in areas with more pediatricians, even when accounting for other factors such as the number of hospitals, imaging technology, insurance coverage and the number of surgeons in an area, according to a study from the Johns Hopkins Children's Center.

30 Dec 2010

CFTR protein regulates inflammation and cell death in emphysema, chronic lung diseases

A team of Johns Hopkins Children's Center researchers has discovered that a protein involved in cystic fibrosis also regulates inflammation and cell death in emphysema and may be responsible for other chronic lung diseases.

29 Dec 2010

DARA BioSciences commences registered public offering

DARA BioSciences, Inc. announced today that it has commenced a registered public offering of up to $4 million of units comprised of shares of Series A convertible preferred stock and warrants to purchase shares of common stock.

29 Dec 2010

Turns mortal heart attacks into non-mortal heart attacks -- NIH study

Three weeks of oral resveratrol or Longevinex- ingestion prior to an induced heart attack returned microRNA activity close to their pre-event levels in excised animal hearts. Among thousands of microRNA's studied, just six were attributed to exerting the majority of the gene-switching effects measured in the animal heart study - four microRNA optimally regulated by Longevinex- and two optimally by plain resveratrol.

28 Dec 2010

Today's opinions: Ariz. hospital and abortion; Wall Street Journal's issues with PolitiFact; Calif.'s anti-smoking success

St. Joseph's Hospital and Medical Center in Phoenix announced on Tuesday that it will continue to provide life-saving abortion care to patients even though it means losing its affiliation with the local Roman Catholic Diocese (12/23).

24 Dec 2010

Gilead stops ARTEMIS-IPF ambrisentan Phase III clinical trial in idiopathic pulmonary fibrosis

Gilead Sciences, Inc. today announced it is stopping ARTEMIS-IPF, the company's ongoing Phase III clinical trial of ambrisentan in patients with idiopathic pulmonary fibrosis (IPF), due to lack of efficacy. This decision follows an interim analysis of unblinded efficacy and safety data by the study's Data Monitoring Committee (DMC) and review of those data by Gilead, which did not show evidence of a treatment benefit in the group of patients randomized to receive ambrisentan.

23 Dec 2010

Vertex announces modification of telaprevir and VX-222 combination Phase 2 trial for treatment of HCV

Vertex Pharmaceuticals Incorporated today announced a modification of its Phase 2 clinical trial evaluating 12-week, response-guided regimens of its lead investigational hepatitis C virus (HCV) protease inhibitor, telaprevir, in combination with its lead investigational HCV polymerase inhibitor, VX-222.

22 Dec 2010

CHMP recommends to grant marketing authorization for Espriet drug against PF to CPF

The Coalition for Pulmonary Fibrosis announced to more than 128,000 patients news that the first drug for the treatment of the deadly lung disease Pulmonary Fibrosis has passed a major hurdle in the European regulatory process and is likely to be approved in all 27 member countries of the European Union.

22 Dec 2010

Pro-Pharmaceuticals, Mount Sinai collaborate to evaluate anti-fibrotic effects of Galectin-targeting compounds

Pro-Pharmaceuticals, Inc., the leading developer of Galectin therapeutics to treat cancer and fibrosis, today announced it has entered into a new research collaboration with Mount Sinai School of Medicine to evaluate in pre-clinical models, the anti-fibrotic effects of several of the Company's novel, Galectin-targeting compounds.

21 Dec 2010

Fibrosis News and Research

Further Reading

Targeted Genetics acquires Biocontrol

BG Medicine enters agreement to develop galectin-3 test for Siemens' automated immunoassay platforms

Findings of AM095 in various in vitro, in vivo models of fibrotic disease published in JPET

Scientists identify prognostic biomarker to treat patients with HCV

Bacteria adopt defence strategy to promote antibiotic resistance

DARA BioSciences provides additional details of DB959 Phase I study for Type 2 Diabetes

DARA BioSciences closes registered public offering

Vitamin D deficiency could be linked to development of certain autoimmune lung diseases

Peptide in blood and tissue inhibits growth of breast tumors

Lyophilized amniotic membrane in strabismus surgery can cause severe fibrosis

Top-line results of TIGER-2 Phase 3 clinical trial for CF treatment

Children more likely to suffer from appendicitis in areas with few pediatricians

CFTR protein regulates inflammation and cell death in emphysema, chronic lung diseases

DARA BioSciences commences registered public offering

Turns mortal heart attacks into non-mortal heart attacks -- NIH study

Today's opinions: Ariz. hospital and abortion; Wall Street Journal's issues with PolitiFact; Calif.'s anti-smoking success

Gilead stops ARTEMIS-IPF ambrisentan Phase III clinical trial in idiopathic pulmonary fibrosis

Vertex announces modification of telaprevir and VX-222 combination Phase 2 trial for treatment of HCV

CHMP recommends to grant marketing authorization for Espriet drug against PF to CPF

Pro-Pharmaceuticals, Mount Sinai collaborate to evaluate anti-fibrotic effects of Galectin-targeting compounds

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News